| First Author | Zhou H | Year | 2024 |
| Journal | Sci Adv | Volume | 10 |
| Issue | 3 | Pages | eadi4298 |
| PubMed ID | 38232158 | Mgi Jnum | J:360111 |
| Mgi Id | MGI:7575259 | Doi | 10.1126/sciadv.adi4298 |
| Citation | Zhou H, et al. (2024) Osteocyte mitochondria inhibit tumor development via STING-dependent antitumor immunity. Sci Adv 10(3):eadi4298 |
| abstractText | Bone is one of the most common sites of tumor metastases. During the last step of bone metastasis, cancer cells colonize and disrupt the bone matrix, which is maintained mainly by osteocytes, the most abundant cells in the bone microenvironment. However, the role of osteocytes in bone metastasis is still unclear. Here, we demonstrated that osteocytes transfer mitochondria to metastatic cancer cells and trigger the cGAS/STING-mediated antitumor response. Blocking the transfer of mitochondria by specifically knocking out mitochondrial Rho GTPase 1 (Rhot1) or mitochondrial mitofusin 2 (Mfn2) in osteocytes impaired tumor immunogenicity and consequently resulted in the progression of metastatic cancer toward the bone matrix. These findings reveal the protective role of osteocytes against cancer metastasis by transferring mitochondria to cancer cells and potentially offer a valuable therapeutic strategy for preventing bone metastasis. |
